SHORT REPORT
Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours
1 Diabetes and Endocrinology Clinical Research Group, University Hospital Aintree, Liverpool, UK
2 Department of Neurosurgery, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK
Correspondence to:
Correspondence to:
C Daousi
Diabetes and Endocrinology Research Group, University Hospital Aintree, Clinical Sciences Centre, 3rd Floor, Lower Lane, Liverpool L9 7AL, UK; cdaousi{at}liverpool.ac.uk
Background: Thyrotropin (TSH)-secreting pituitary adenomas (TSHomas) are rare tumours that can be invasive. It has been suggested that thyroid surgery or radioiodine treatment should not be considered in patients with such tumours as these treatments may facilitate rapid and aggressive tumour expansion.
Aim: To study the effects of thyroid ablative treatment on tumour size and thyroid status in two patients with TSHomas in whom the size of the adenoma was clearly documented before treatment was started.
Methods: Patients studied were: (1) a female patient with a TSHoma who declined to undergo pituitary surgery and underwent a total thyroidectomy instead and (2) a male patient who opted for radioiodine treatment for his recurrent TSHoma. Changes in tumour size on serial magnetic resonance imaging scans, and restoration of euthyroidism were studied.
Results: No marked changes in tumour size or features of aggressiveness occurred in these patients over periods of 8 and 12 years. Euthyroidism was restored and maintained in both patients.
Conclusions: Ablative thyroid treatment can be a safe and successful option to treat TSHomas, but long-term and close follow-up of these patients is mandatory to ensure that the size and behaviour of the tumours do not change markedly.
Abbreviations:
SU,
-subunit; FSH, follicle-stimulating hormone; FT3, free tri-iodothyronine; FT4, free thyroxine; MRI, magnetic resonance imaging; TSH, thyrotropin; TSHoma, TSH-secreting pituitary adenoma
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
-
Buchfelder, M, Weigel, D, Droste, M, Mann, K, Saller, B, Brubach, K, Stalla, G K, Bidlingmaier, M, Strasburger, C J, on behalf of the investigators of the German Pegvi,
(2009). Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol
161: 27-35
[Abstract] [Full Text] -
Mittra, E. S., Niederkohr, R. D., Rodriguez, C., El-Maghraby, T., McDougall, I. R.
(2008). Uncommon Causes of Thyrotoxicosis. JNM
49: 265-278
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
